Marquez Jorge, Weldemariam Mehari M, Dong Jianping, Hayashi Jun, Kane Maureen A, Serrero Ginette
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States of America.
Target Discovery Division, A&G Pharmaceutical, Inc., Columbia, Maryland 21045, United States of America.
ACS Omega. 2024 Mar 15;9(12):14381-14387. doi: 10.1021/acsomega.4c00042. eCollection 2024 Mar 26.
Prostaglandin F2 receptor negative regulator (PTGFRN) is a transmembrane protein whose expression has been previously implicated in cancer metastasis. However, the exact molecular mechanisms by which PTGFRN influences cancer progression are still unknown. As such, our laboratory set out to investigate how PTGFRN knockdown affected the expression of other proteins. We also carried out coimmunoprecipitation experiments using a monoclonal anti-PTGFRN antibody. We employed mass spectrometry-based proteomics for both experiments to identify proteins that were associated with PTGFRN. Our data show that PTGFRN knockdown increased pathways related to innate immune responses and decreased pathways associated with the synthesis of metabolic precursors and protein processing, among others. Additionally, the coimmunoprecipitation experiments indicated that PTGFRN is associated with proteins involved in processing and metabolism, as well as VEGF signaling molecules. These results highlight the role of PTGFRN as a protein processing regulator, which may be influencing cancer progression.
前列腺素F2受体负调控因子(PTGFRN)是一种跨膜蛋白,其表达先前已被证明与癌症转移有关。然而,PTGFRN影响癌症进展的确切分子机制仍不清楚。因此,我们实验室着手研究PTGFRN基因敲低如何影响其他蛋白质的表达。我们还使用单克隆抗PTGFRN抗体进行了免疫共沉淀实验。我们在这两个实验中都采用了基于质谱的蛋白质组学技术来鉴定与PTGFRN相关的蛋白质。我们的数据表明,PTGFRN基因敲低增加了与先天免疫反应相关的通路,减少了与代谢前体合成和蛋白质加工等相关的通路。此外,免疫共沉淀实验表明,PTGFRN与参与加工和代谢的蛋白质以及血管内皮生长因子(VEGF)信号分子有关。这些结果突出了PTGFRN作为一种蛋白质加工调节因子的作用,这可能正在影响癌症进展。